Y-Biologics Statistics
Total Valuation
Y-Biologics has a market cap or net worth of KRW 150.99 billion.
Market Cap | 150.99B |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Y-Biologics has 14.95 million shares outstanding.
Current Share Class | 14.95M |
Shares Outstanding | 14.95M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 29.34% |
Owned by Institutions (%) | 3.57% |
Float | 10.49M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 30.03 |
PB Ratio | 8.56 |
P/TBV Ratio | 9.16 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.28, with a Debt / Equity ratio of 0.04.
Current Ratio | 8.28 |
Quick Ratio | 8.07 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | -0.10 |
Interest Coverage | -265.88 |
Financial Efficiency
Return on equity (ROE) is -31.88% and return on invested capital (ROIC) is -23.69%.
Return on Equity (ROE) | -31.88% |
Return on Assets (ROA) | -22.15% |
Return on Invested Capital (ROIC) | -23.69% |
Return on Capital Employed (ROCE) | -44.59% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.22 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.56% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -8.56% |
50-Day Moving Average | 8,899.80 |
200-Day Moving Average | 8,706.50 |
Relative Strength Index (RSI) | 46.40 |
Average Volume (20 Days) | 164,602 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Y-Biologics had revenue of KRW 5.03 billion and -6.70 billion in losses. Loss per share was -634.34.
Revenue | 5.03B |
Gross Profit | 3.75B |
Operating Income | -8.27B |
Pretax Income | -6.70B |
Net Income | -6.70B |
EBITDA | -6.29B |
EBIT | -8.27B |
Loss Per Share | -634.34 |
Balance Sheet
The company has 10.38 billion in cash and 739.55 million in debt, giving a net cash position of 9.64 billion or 645.16 per share.
Cash & Cash Equivalents | 10.38B |
Total Debt | 739.55M |
Net Cash | 9.64B |
Net Cash Per Share | 645.16 |
Equity (Book Value) | 17.64B |
Book Value Per Share | 1,128.58 |
Working Capital | 9.50B |
Cash Flow
In the last 12 months, operating cash flow was -4.75 billion and capital expenditures -2.47 billion, giving a free cash flow of -7.21 billion.
Operating Cash Flow | -4.75B |
Capital Expenditures | -2.47B |
Free Cash Flow | -7.21B |
FCF Per Share | -482.54 |
Margins
Gross margin is 74.67%, with operating and profit margins of -164.54% and -133.25%.
Gross Margin | 74.67% |
Operating Margin | -164.54% |
Pretax Margin | -133.25% |
Profit Margin | -133.25% |
EBITDA Margin | -125.02% |
EBIT Margin | -164.54% |
FCF Margin | n/a |
Dividends & Yields
Y-Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -4.44% |
FCF Yield | -4.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Y-Biologics has an Altman Z-Score of 27.48 and a Piotroski F-Score of 1.
Altman Z-Score | 27.48 |
Piotroski F-Score | 1 |